Treatment group | Trial day 8 | Trial day 22 |
---|
 | Before dosing | 3 hours after dosing | n | Before dosing | 3 hours after dosing | n |
---|
ABT-116
| 0 ± 0 | 569 ± 294 | 12# | 1,277 ± 644 | 1,589 ± 700*** | 12# |
ABT-116 metabolite
| 0 ± 0 | 115 ± 63 | 11# | 592 ± 256 | 538 ± 244*** | 11# |
Carprofen
| 0 ± 0 | 3,386 ± 2,282 | 11# | 3,752 ± 2,211 | 4,779 ± 2,789 | 11# |
Tramadol
| 0.0 ± 0.0 | 39.3 ± 35.3 | 11# | 0.6 ± 1.9 | 7.1 ± 8.8** | 11# |
- Note: All values represent mean ± standard deviation in ng/ml. n – sample number. #One dog in the treatment group was excluded because high drug concentrations were detected in the pre-treatment sample and low concentrations in one or more post-treatment samples. ABT-116, Carprofen, and Tramadol were not detected in any plasma sample from the Placebo group. Significance of changes in plasma drug concentrations from post-treatment sample on Day 8 is indicated as follows: ** - P < 0.01; *** - P < 0.001.